The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

X.g

Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)

Publications

Hamzaoglu H, Cooper J, Alsahli M, Falchuk KR, Peppercorn MA, Farrell RJ

Safety of infliximab in Crohn's disease: a large single-center experience.

Inflammatory bowel diseases. 2010;16(12):2109-16

Bremmer MS, Bremmer SF, Baig-Lewis S, Simpson EL

Are biologics safe in the treatment of atopic dermatitis? A review with a focus on immediate hypersensitivity reactions.

Journal of the American Academy of Dermatology. 2009;61(4):666-76

Benucci M, Manfredi M, Saviola G, Baiardi P, Campi P

Correlation between atopy and hypersensitivity reactions during therapy with three different TNF-alpha blocking agents in rheumatoid arthritis.

Clinical and experimental rheumatology. 2009;27(2):333-6

Descotes J, Gouraud A

Clinical immunotoxicity of therapeutic proteins.

Expert opinion on drug metabolism & toxicology. 2008;4(12):1537-49

Cheifetz A, Smedley M, Martin S, Reiter M, Leone G, Mayer L, Plevy S

The incidence and management of infusion reactions to infliximab: a large center experience.

The American journal of gastroenterology. 2003;98(6):1315-24